title: Liver abscess formation after local treatment of liver tumors.
abstract: Our goal was to determine a subset of patients at high risk of developing liver abscesses after local treatment of liver tumors (LTLT) and establish guidelines for the conduct of LTLT in the safest conditions in such patients. Five hundred sixty-one LTLT, 489 transhepatic arterial chemoembolizations (TAC, 10 hepatic embolizations, and 62 percutaneous intratumor injections (PIT), were retrospectively reviewed for liver parenchyma necrosis and abscess formation. Four patients developed abscesses, three after TAC and one after PIT. Despite broad-spectrum antibiotherapy, percutaneous drainage, and surgery, two patients died. A left hepatectomy was required in the other two patients for cure. All four patients had a carcinoid or a neuroendocrine pancreatic tumor. Three out of four patients had bilioenteric anastomoses, and the fourth had recently undergone cholecystectomy and papillotomy. A Lipiodol/doxorubicin mixture without any particulate embolization was injected in the three patients who developed abscesses after TAC. LTLT in patients with bilio enteric anastomosis or papillotomy and/or neuroendocrine or carcinoid tumor should be performed with strict precautions during the procedure and for peri-procedural care.
authors.affiliation: Department of Interventional Radiology, Gustave Roussy Institute, VillejuiF, Fance.
authors.forename: T
authors.initials: T
authors.lastname: de Baère
authors.forename: A
authors.initials: A
authors.lastname: Roche
authors.forename: J M
authors.initials: JM
authors.lastname: Amenabar
authors.forename: C
authors.initials: C
authors.lastname: Lagrange
authors.forename: M
authors.initials: M
authors.lastname: Ducreux
authors.forename: P
authors.initials: P
authors.lastname: Rougier
authors.forename: D
authors.initials: D
authors.lastname: Elias
authors.forename: P
authors.initials: P
authors.lastname: Lasser
authors.forename: C
authors.initials: C
authors.lastname: Patriarche
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D015552:Injections, Intralesional; D007414:Intestinal Neoplasms; D008100:Liver Abscess / Q000209:etiology* / Q000517:prevention & control; D008113:Liver Neoplasms / Q000150:complications / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D010190:Pancreatic Neoplasms; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents